Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439128 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL24047701 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL23695127 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL23695128 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL31320075 | 0.87 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL17730541 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL23487150 | 0.87 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL29601341 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL29785811 | 0.86 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL25866393 | 0.85 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | HSD17B10 166/4885SMN1; SMN2 4624/4885BTK 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.